Stay updated on Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial page.

Latest updates to the Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial page
- Check5 days agoChange DetectedNo substantive changes detected in the study record; core fields such as title, conditions, interventions, outcomes, eligibility, and locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check34 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference2%

- Check41 days agoChange DetectedThe page now displays Revision: v3.1.0 and removes multiple drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) indicating a narrowing of content scope with a version update.SummaryDifference0.2%

- Check55 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.SummaryDifference0.1%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check70 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations in Belgium, as well as new medical topics related to diabetes and drug safety. The previous location terms and outdated revision information have been removed.SummaryDifference2%

Stay in the know with updates to Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial page.